Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β

Journal of Neuroinflammation

Volumn 14, Issue 1, 2017, Pages

  Lee, Paul R ^a   Johnson, Tory P ^a   Gnanapavan, Sharmilee ^b   Giovannoni, Gavin ^b   Wang, Tongguang ^a   Steiner, Joseph P ^a   Medynets, Marie ^a   Vaal, Mark J ^a   Gartner, Valerie ^c   Nath, Avindra ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Granzyme B; Interleukin 1; Multiple sclerosis; Neuroinflammation; Neurotoxicity; Protease activated receptor

Indexed keywords

GRANZYME B; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; LAMOTRIGINE; PROTEINASE ACTIVATED RECEPTOR 1; GRANZYME; GZMB PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CASE REPORT; CEREBROSPINAL FLUID; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTOXICITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VERY ELDERLY; AGONISTS; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GRANZYMES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTOR, PAR-1;

EID: 85021264533     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-017-0901-y     Document Type: Article

References (50)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol. 1992;31:333-6.
2. Rissanen E, Tuisku J, Rokka J, et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195. J Nucl Med. 2014;55:939-44.
3. Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:1082-91.
4. Fernández-Jaén A, Fernández-Mayoralas DM, Fernández-Perrone AL, et al. Cortical thickness at the time of the initial attack in two patients with paediatric relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. 2014;18:295-300. doi: 10.1016/j.ejpn.2013.12.002.
5. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74:1868-76.
6. Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain. 2012;135:2952-61.
7. Klaver R, De Vries HE, Schenk GJ, Geurts JJ. Grey matter damage in multiple sclerosis: a pathology perspective. Prion. 2013;7:66-75.
8. Wang H, Reiser G. Thrombin signaling in the brain: the role of protease-activated receptors. Biol Chem. 2003;384:193-202.
9. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-68.
10. Wang T, Lee MH, Choi E, et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS One. 2012. doi: 10.1371/journal.pone.0043950.
11. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001;431:347-61.
12. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69-86.
13. Olianas MC, Dedoni S, Onali P. Proteinase-activated receptors 1 and 2 in rat olfactory system: layer-specific regulation of multiple signaling pathways in the main olfactory bulb and induction of neurite retraction in olfactory sensory neurons. Neuroscience. 2007;146:1289-301.
14. Olson EE, Lyuboslavsky P, Traynelis SF, McKeon RJ. PAR-1 deficiency protects against neuronal damage and neurologic deficits after unilateral cerebral hypoxia/ischemia. J Cereb Blood Flow Metab. 2004;24:964-71.
15. Almonte AG, Qadri LH, Sultan FA, Watson JA, Mount DJ, Rumbaugh G, Sweatt JD. Protease-activated receptor-1 modulates hippocampal memory formation and synaptic plasticity. J Neurochem. 2013;124:109-22.
16. Acharjee S, Zhu Y, Maingat F, et al. Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain. 2011;134:3209-21.
17. Donovan FM, Pike CJ, Cotman CW, Cunningham DD. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J Neurosci. 1997;17:5316-26.
18. Wang T, Lee MH, Johnson T, et al. Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci. 2010;30:5020-7.
19. Sellebjerg F, Bendtzen K, Christiansen M, Frederiksen J. Cytokines and soluble IL-4 in patients with acute optic neuritis and multiple sclerosis. Eur J Neurol. 1997;4:59-67.
20. Mehta PD, Kulczycki J, Mehta SP, et al. Increased levels of interleukin-1beta and soluble intercellular adhesion molecule-1 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis. J Infect Dis. 1997;175:689-92.
21. Rossi S, Furlan R, De Chiara V, et al. Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012;71:76-83.
22. Seppi D, Puthenparampil M, Federle L, et al. Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset. J Neuroimmunol. 2014;270:56-60.
23. Takahashi Y, Mine J, Kubota Y, Yamazaki E, Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF. Epilepsia. 2009;50:1419-31.
24. Gnanapavan S, Grant D, Morant S, et al. Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. PLoS One. 2013. doi: 10.1371/journal.pone.0070019.
25. Jia Y, Wu T, Jelinek CA, et al. Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics. 2012. doi: 10.1186/1559-0275-9-9.
26. Shimormura N, Sasho M, Kayano A, inventors; Esai Co., Ltd., assignee, et al. Methods for producing cyclic benzamidine derivatives, United States patent US CA2515715 A1. 2004.
27. Hedreen JC. What was wrong with the Abercrombie and empirical cell counting methods? A review. Anat Rec. 1998;250:373-80.
28. Bae M, Patel N, Xu H, et al. Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection. J Neurosci. 2014;34:11485-503.
29. Wang T, Allie R, Conant K, et al. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J. 2006;20:1209-11.
30. Cacabelos R, Barquero M, García P, et al. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol. 1991;13:455-8.
31. Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:1101-7.
32. Junge CE, Lee CJ, Hubbard KB, et al. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol. 2004;188:94-103.
33. Bush WS, McCauley JL, DeJager PL, et al. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun. 2011;12:335-40.
34. Di Prisco S, Merega E, Milanese M, et al. CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. Neuropharmacology. 2013;75:337-46.
35. Evans J, Ko Y, Mata W, et al. Arachidonic acid induces brain endothelial cell apoptosis via p38-MAPK and intracellular calcium signaling. Microvasc Res. 2015;98:145-58.
36. Xue M, Hollenberg MD, Demchuk A, Yong VW. Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice. Stroke. 2009;40:2199-204.
37. Burda JE, Radulovic M, Yoon H, Scarisbrick IA. Critical role for PAR-1 in kallikrein 6-mediated oligodendrogliopathy. Glia. 2013;61:1456-70.
38. da Lee Y, Park KW, Jin BK. Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions. Biochem Biophys Res Commun. 2006;346:727-38.
39. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res. 2012;34(9):854-8.
40. Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005;64:1267-9.
41. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology. Vascul Pharmacol. 2014;62:72-81.
42. Kai Y, Hirano K, Maeda Y, et al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke. 2007;38:3259-65.
43. Rossi S, Studer V, Motta C, et al. Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis. J Neuroinflammation. 2014;11:32.
44. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31:439-47.
45. Dujmovic I, Mangano K, Pekmezovic T, et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 2009;207:101-6.
46. Voltz R, Hartmann M, Spuler S, et al. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg Psychiatry. 1997;62:200-1.
47. Takahashi JL, Giuliani F, Power C, et al. Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol. 2003;53:588-95.
48. Kroner A, Ip CW, Thalhammer J, et al. Ectopic T-cell specificity and absence of perforin and granzyme B alleviate neural damage in oligodendrocyte mutant mice. Am J Pathol. 2010;176:549-55.
49. Romme Christensen J, Börnsen L, Ratzer R, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013;8:e57820.
50. De Biasi S, Simone AM, Nasi M, et al. iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. Front Immunol. 2016;7:555.